Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1

Abstract Introduction Once-daily fixed-dose combinations (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and children with HIV weighing ≥ 6 kg. This analysis assessed the ability of previously developed ABC, DTG, and 3TC pediatric pop...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta, Mark Bush, Helena Rabie, Patricia Flynn, Tim R. Cressey, Edward P. Acosta, Kristina M. Brooks, for the IMPAACT 2019 Study Team
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2024-07-01
Edice:	Infectious Diseases and Therapy
Témata:	Dolutegravir Abacavir Lamivudine Population pharmacokinetics HIV-1 Pediatrics
On-line přístup:	https://doi.org/10.1007/s40121-024-01008-y
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!